MAPrc’s researchers are currently working on a number of projects investigating new diagnostic and treatment methods for people experiencing depression

The following projects are currently recruiting participants. Please contact us if you wish to receive futher information or take part in a project.

Pharmaceutical Trials in Depression

MAPrc's Psychopharmacology team conducts trials of new medications for treating depression in partnership with pharmaceutical companies who develop and manufacture cutting edge new medicines. These trials are randomised controlled trials (RCT's) and provide participants with access to the latest treatments for depression under controlled and safe conditions. 

The aim of randomised controlled trials is to validate the effectiveness of new medicines for treating depression.

All randomised controlled trials (RCT's) have strict selection criteria to ensure the new medicine is trialled in specific subgroups of people, for example people with treatment resistent depression will require that the participant has trialled 2 or more existing treatments to be eligible to participate.

Trials of the new medicine are usually randomised against a comparator medicine that has already been shown to be effective, or against a placebo. Participants will visit our clinic for an initial screening visit, and then if eligible, for a randomisation visit where they will be commenced on the new medicine or it's comparator. Participants will attend our clinic each week for a check up and to complete assessments of the treatmente effectiveness. Saftey testing is also completed at each visit. 

Participants are reimbursed between $30 - $40 for each visit to the clinic, and receive all medication free of charge.

To find out more about participating in one of our medication trials contact:

Esketamine for Depression
This clinical research study will look at the long-term effectiveness and safety of an investigational medication (Esketamine given as a nasal spray) in patients with depression who have not responded to prior treatment with at least two antidepressants. For further details please click here or contact Caitlin Finney on 9076 6564 or email

Tibolone and Escitalopram in Perimenopausal Depression
Clinical trials of a hormone treatment called Tibolone, for the treatment of depression in peri and post menopause. To take part in this study you must be physically well, aged 45-65 be experiencing depression and able to give informed consent. For further details click here or contact Jasmin Grigg on 9076 6564 or email

Transcranial magnetic stimulation (TMS) for Depression
TMS uses magnetic pulses to change activity in the areas of the brain thought to be related to this illness, and is being investigated as an alternative treatment for people, who have not responded to antidepressant medication. For further information click here or contact the TMS team on 90766595 or email

Magnetic Seizure Therapy (MST) for Depression
MST uses a magnetic field to induce a seizure for therapeutic purposes, and is being investigated as an alternative to Electroconvulsive therapy for severe depression. For further information click here or contact the TMS team on 90766595 or email

Deep Brain Stimulation for Depression
Deep Brain Stimulation involves the precise implantation of very small electrodes into specific areas of the brain, in an attempt to change activity in those and related areas and improve the symptoms of very severe, treatment resistant depression.
As DBS is considered a treatment of last resort, only individuals who have trialled all less invasive antidepressant treatments and remained severely depressed can be considered for the procedure, This means having trialled multiple medications for all antidepressant drug classes, combinations of antidepressant medications, cognitive behavioural therapy, transcranial magnetic stimulation and extensive electroconvulsive therapy (ECT).
At MAPrc we have been investigating the use of DBS for the treatment of severe treatment resistant depression for a number of years and have recently finished recruitment for a small inital pilot study. Analysis of the results of this study are currently underway and we are applying for funding to conduct a larger and longer term investigation. 
Whilst we seek further funding, we are not actively evaluating new patients for this procedure. However if you wish to be considered for the program in the future, and you have tried all of the treatments listed above, you can have your psychiatrist send a detailed referral letter to Prof. Paul Fitzgerald at .
This will be kept on record and if the program recommences in the future you will be contacted. 

EVestG (ElectrovestibuloGraphy)
A new technique, EVestG (ElectrovestibuloGraphy) in being investigated as a possible objective method for diagnosing participants with depression. For further information click here or contact MAPrc on 9076 6564 or email 

Mood and Oral Contraceptives 
An observational study of women taking / not taking hormonal contraception (i.e. COCP, POP, Implanon, DMPA) exploring current mood & risk and resistance factors for adverse mood change. To take part in this study you must be a female 18 years of age or older, able to give informed consent and not currently pregnant, breast-feeding or menopausal. For further information click here or contact Emmy Gavrilidis on 9076 6913 or email  

NRAMP - National Register of Antipsychotic Medication in Pregnancy
An observational study for women who are taking or have taken antipsychotic medications during their pregnancy. For further information click here or contact Heather Gilbert 9076 6591 or email 

Auditory verbal hallucinations
 A large-scale phenomenological study investigating the physical characteristics as well as underlying beliefs related to auditory verbal hallucinations, also known as 'voice-hearing' experiences, in diverse clinicial populations, including bipolar disorder, major depression and schizophrenia, as well as non-clinical groups. For further information click here or contact Dr Wei Lin Toh on 9076 5712 or 




 MAPrc Monash Alfred Psychiatry Research Centre, Level 4, 607 St Kilda Road, Melbourne 3004

 © MAPrc 2013. Designed and hosted by Infoxchange Australia